<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00394628</url>
  </required_header>
  <id_info>
    <org_study_id>021-003</org_study_id>
    <nct_id>NCT00394628</nct_id>
  </id_info>
  <brief_title>AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme</brief_title>
  <official_title>A Phase 1b/2a, Multicenter, Open-Label Study of AQ4N in Combination With Radiation Therapy and Temozolomide, to Evaluate the Safety, Tolerability, and Efficacy in Subjects With Newly Diagnosed Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novacea</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novacea</source>
  <brief_summary>
    <textblock>
      Phase 1b of the study, will evaluate the safety and tolerability of AQ4N treatment at three&#xD;
      different dose levels.&#xD;
&#xD;
      Phase 2a of the study, will further evaluate the safety, tolerability, and in addition&#xD;
      efficacy of AQ4N treatment at a tolerated dose selected from Phase 1b.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2006</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1b: Evaluation of the safety and tolerability of AQ4N in combination with radiation therapy and temozolomide (TEMODARÂ®)for the treatment of glioblastoma multiforme (GBM). Dose levels for the Phase 2a will be selected.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2a: Rate of progression-free survival at 6 months.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 2a: Rate of progression-free survival at 12 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects alive at 12 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of overall survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AQ4N</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven intracranial Glioblastoma Multiforme (GBM) with diagnosis&#xD;
             established by biopsy or resection within 5 weeks prior to enrollment.&#xD;
&#xD;
          -  Cranial MRI or contrast CT performed 14 days prior to study entry. Subjects without&#xD;
             measurable or assessable disease are eligible.&#xD;
&#xD;
          -  Plan to begin partial brain radiotherapy within 24-72 hours after beginning AQ4N, and&#xD;
             within 35 days (5 weeks) of the surgery, or if surgery cannot be performed, the biopsy&#xD;
             that confirms GBM diagnosis. Radiation therapy must be given by external beam to a&#xD;
             partial brian field in daily fractions of 2.0 Gy, to a planned total dose to the tumor&#xD;
             of 60.0 Gy over 6 weeks.&#xD;
&#xD;
          -  Age equal to or greater than 18 years and life expectancy &gt; 10 weeks.&#xD;
&#xD;
          -  Karnofsky performance status of &gt; 60.&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal functions (tests must be performed within 14&#xD;
             days prior to enrollment).&#xD;
&#xD;
          -  Negative serum or urine pregnancy test (females of childbearing potential only).&#xD;
&#xD;
          -  Willingness to use effective contraception (both males and females of child-bearing&#xD;
             potential) throughout the study and for at least 2 months after study treatment.&#xD;
&#xD;
          -  Able and willing to give informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous radiotherapy to the brain.&#xD;
&#xD;
          -  Previous cytotoxic drug therapy, non-cytotoxic drug therapy, or experimental drug&#xD;
             therapy directed against the brain tumor. Subjects who received Gliadel wafers will be&#xD;
             excluded.&#xD;
&#xD;
          -  Subjects previously treated with enzyme-induced antiepileptic drugs (EIAEDs) must have&#xD;
             discontinued treatment with these agent(s) greater than or equal to 2 weeks prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  A history of any other primary malignancy that has not been treated with curative&#xD;
             intent and that has not been in complete remission for at least 2 years (exempt from&#xD;
             the two year limit are non-melanoma skin cancer and cervical carcinoma in-situ on&#xD;
             biopsy or a squamous intraepithelial lesion on PAP smear).&#xD;
&#xD;
          -  Active infection.&#xD;
&#xD;
          -  Any significant medical illnesses or toxicities that in the investigator's opinion&#xD;
             cannot be adequately controlled with appropriate therapy or would compromise the&#xD;
             subjects' ability to tolerate this therapy. Subjects must not have any disease that&#xD;
             will obscure toxicity or dangerously alter drug metabolism, e.g. congestive heart&#xD;
             failure, moderate to severe liver and renal disease, other cancers.&#xD;
&#xD;
          -  Cardiac ejection fraction (LVEF) by multiple gated acquisition scan (MUGA) less than&#xD;
             the institutional lower limit of normal.&#xD;
&#xD;
          -  Prior investigational therapy within the past 28 days.&#xD;
&#xD;
          -  Prior AQ4N therapy.&#xD;
&#xD;
          -  Hypersensitivity to AQ4N or to any ingredients contained in the drug formulation.&#xD;
&#xD;
          -  Hypersensitivity to temozolomide or to any ingredients contained in the drug&#xD;
             formulation and dacarbazine (DTIC).&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emese Filka</last_name>
      <phone>310-794-3521</phone>
    </contact>
    <investigator>
      <last_name>Tim Clughsey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lilia Gallot</last_name>
      <phone>312-695-1363</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey Raizer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health Systems</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Ann Beasse</last_name>
      <phone>313-916-3731</phone>
      <email>rbeasse1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Tom Mikkelsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Velmeca McCrea</last_name>
      <phone>919-684-5632</phone>
      <email>velmeca.mccrea@duke.edu</email>
    </contact>
    <investigator>
      <last_name>David Reardon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Peschka, RN</last_name>
      <phone>214-820-8685</phone>
    </contact>
    <investigator>
      <last_name>Karen Fink, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <study_first_submitted>October 31, 2006</study_first_submitted>
  <study_first_submitted_qc>October 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2006</study_first_posted>
  <last_update_submitted>May 29, 2007</last_update_submitted>
  <last_update_submitted_qc>May 29, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2007</last_update_posted>
  <keyword>Glioblastoma Multiforme</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>temozolomide</keyword>
  <keyword>adjuvant temozolomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

